Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. [electronic resource]
Producer: 20190403Description: 154-161 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzimidazoles -- administration & dosage
- Breast Neoplasms -- drug therapy
- Breast Neoplasms, Male -- drug therapy
- Carboplatin -- administration & dosage
- Female
- Genes, BRCA1
- Genes, BRCA2
- Germ-Line Mutation
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local -- drug therapy
- Paclitaxel -- administration & dosage
- Placebos
- Single-Blind Method
- Temozolomide -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.